Second Malignant Neoplasm Occurring Years After Hyperthermic Isolated Limb Perfusion for Melanoma
Author(s) -
C. Lenormand,
Candice Pelletier,
A.-L. Goeldel,
MariePierre Chenard,
Florent Grange
Publication year - 2010
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archdermatol.2010.3
Subject(s) - medicine , melanoma , dacarbazine , limb perfusion , stage (stratigraphy) , melphalan , chemotherapy , oncology , skin cancer , surgery , dermatology , cancer , perfusion , cancer research , paleontology , biology
Hyperthermic isolated limb perfusion (HILP) is a useful therapeutic option in patients with locally advanced melanoma of the extremities. Because HILP allows very high doses of cytotoxic agents to be administered without systemic leakage, the theoretical risk of a secondary malignant neoplasm is real, particularly in the treated limb. Such an event has never been reported to our knowledge, however, possibly in part because survival in these patients is often too short to permit the development of chemo-induced cancers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom